StockMarketWire.com - ANGLE said new research by Heinrich Heine University of Duesseldorf demonstrated the the measurement of key proteins in breast cancer using Parsortix, which may advise therapy decisions in breast cancer treatment.

It said the research had been published in the International Journal of Molecular Science and was available at http://angleplc.com/library/publications/.

The group said: "Duesseldorf have shown in their study of 47 metastatic breast cancer patients that the Parsortix system harvests clinically relevant cancer cells for analysis that other systems miss (EpCAM low/negative CTCs) and confirmed this by demonstrating that Parsortix can harvest such cells from the waste product of the leading antibody-based system.

"Duesseldorf established protocols combining Parsortix with the downstream CellCelector micromanipulator to enable the individual processing of CTCs (circulating tumour cells) as single cells so that the heterogeneity of the patient's cancer can be investigated.

"The downstream analysis included Sanger sequencing investigating the presence or absence of PIK3CA, one of the most frequently mutated genes in invasive breast cancer which confers remarkable selective growth gain to the cell.

"In the publication, the researchers state that the mutational analysis of the PIK3CA within EpCAM low/negative CTCs (i.e. CTCs that can be harvested by Parsortix but not by antibody-based systems) may allow personalised HER2-targeted therapies."

Duesseldorf is a customer of ANGLE and its research work is independent of the company.

ANGLE founder and chief executive, Andrew Newland, said: "These results published in a leading peer-reviewed journal are further demonstration of the key advantages of the Parsortix system.

"Our strategy of getting the Parsortix system widely used in leading cancer research centres is working well with customers driving growth in the body of evidence behind Parsortix."




Story provided by StockMarketWire.com